These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 6334491)
21. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group. Bourgault AM; Lamothe F J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324 [TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibility of the Bacteroides fragilis group in community hospitals. File TM; Thomson RB; Tan JS; Salstrom SJ; Jacobs GA; Johnson L; Tan L Diagn Microbiol Infect Dis; 1986 Nov; 5(4):317-22. PubMed ID: 3465493 [TBL] [Abstract][Full Text] [Related]
23. Antimicrobial resistance of strains of the Bacteroides fragilis group isolated from the intestinal tract of children and adults in Brazil. Avelar KE; Vieira JM; Antunes LC; Lobo LA; Antunes EN; Domingues RM; Ferreira MC Int J Antimicrob Agents; 2001 Aug; 18(2):129-34. PubMed ID: 11516935 [TBL] [Abstract][Full Text] [Related]
24. Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group. Lamothe F; Auger F; Lacroix JM Antimicrob Agents Chemother; 1984 May; 25(5):662-5. PubMed ID: 6732233 [TBL] [Abstract][Full Text] [Related]
25. [Susceptibility of the Bacteroides fragilis group to 10 antibiotics. Results of 4 laboratories in Austria]. Mittermayer H; Rotter M; Riezinger F; Thiel W; Stanek G Zentralbl Bakteriol Mikrobiol Hyg A; 1986 Nov; 262(4):500-11. PubMed ID: 3799095 [TBL] [Abstract][Full Text] [Related]
26. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Snydman DR; Jacobus NV; McDermott LA; Supran S; Cuchural GJ; Finegold S; Harrell L; Hecht DW; Iannini P; Jenkins S; Pierson C; Rihs J; Gorbach SL Antimicrob Agents Chemother; 1999 Oct; 43(10):2417-22. PubMed ID: 10508018 [TBL] [Abstract][Full Text] [Related]
27. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea. Roh KH; Kim S; Kim CK; Yum JH; Kim MS; Yong D; Lee K; Kim JM; Chong Y Korean J Lab Med; 2009 Aug; 29(4):293-8. PubMed ID: 19726890 [TBL] [Abstract][Full Text] [Related]
28. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group. Brook I Rev Infect Dis; 1991; 13(6):1170-80. PubMed ID: 1775850 [TBL] [Abstract][Full Text] [Related]
29. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents. Aldridge KE; Henderberg A; Sanders CV J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826 [TBL] [Abstract][Full Text] [Related]
30. Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agents. Horn R; Lavallée J; Robson HG Antimicrob Agents Chemother; 1992 Sep; 36(9):2051-3. PubMed ID: 1416899 [TBL] [Abstract][Full Text] [Related]
31. Characterization of beta-lactamases in clinical isolates of Bacteroides. Eley A; Greenwood D J Antimicrob Chemother; 1986 Sep; 18(3):325-33. PubMed ID: 3490466 [TBL] [Abstract][Full Text] [Related]
32. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989. Betriu C; Cabronero C; Gomez M; Picazo JJ Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757 [TBL] [Abstract][Full Text] [Related]
33. Biochemical characterization and in vitro determination of antibiotic susceptibility of clinical isolates of Bacteroides fragilis. Dornbusch K; Nord CE; Wadström T Scand J Infect Dis; 1974; 6(3):253-8. PubMed ID: 4496865 [No Abstract] [Full Text] [Related]
34. Susceptibility of cefotetan and Sch 34343 to beta-lactamases produced by strains of Bacteroides that hydrolyse cefoxitin or imipenem. Andrew JH; Greenwood D J Antimicrob Chemother; 1987 May; 19(5):591-5. PubMed ID: 3497146 [TBL] [Abstract][Full Text] [Related]
35. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species. Byun JH; Kim M; Lee Y; Lee K; Chong Y Ann Lab Med; 2019 Mar; 39(2):190-199. PubMed ID: 30430782 [TBL] [Abstract][Full Text] [Related]
36. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246 [TBL] [Abstract][Full Text] [Related]
37. A multicentre survey of the antibiotic susceptibility of clinical Bacteroides species from Hungary. Sárvári KP; Sóki J; Kristóf K; Juhász E; Miszti C; Latkóczy K; Melegh SZ; Urbán E Infect Dis (Lond); 2018 May; 50(5):372-380. PubMed ID: 29303023 [TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989. Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621 [TBL] [Abstract][Full Text] [Related]
39. beta-lactamases in bacteroides. Nord CE; Olsson B; Dornbusch K Scand J Infect Dis Suppl; 1978; (13):27-32. PubMed ID: 28561 [TBL] [Abstract][Full Text] [Related]
40. In vitro activities of faropenem against 579 strains of anaerobic bacteria. Wexler HM; Molitoris D; St John S; Vu A; Read EK; Finegold SM Antimicrob Agents Chemother; 2002 Nov; 46(11):3669-75. PubMed ID: 12384389 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]